Archil Jaliashvili: Hemopure and the Future of Oxygen Delivery in Severe Bleeding
Archil Jaliashvili, Co-owner, General Manager of SkinAI, Co-Chief Executive Officer at GeoBio Pharm, shared a post on LinkedIn:
”A patient with catastrophic hemorrhage survived after Cleveland Clinic used Hemopure, when conventional blood transfusion was not an option.
For decades, we spoke about ‘blood substitutes.’
But the real medical target was never blood itself.
The target is oxygen delivery.
We should not only manage hemoglobin numbers.
We must manage tissue oxygenation.
The future of transfusion medicine will not be only about blood.
It will be about precision oxygen delivery.
For emerging BHOC biological hemoglobin oxygen carrier biosimilar and new-generation platforms, this is another important real-world signal that the field is evolving toward solving major global unmet medical needs:
- Severe hemorrhage
- Trauma and emergency care
- Battlefield medicine
- Maternal bleeding
- Organ preservation and perfusion
- Veterinary critical care
- Remote and disaster medicine
Sometimes one clinical case says more than a thousand theoretical discussions.”
Stay updated with Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026